Cathie Wood, founder of ARK Invest, forecasts Bitcoin could hit around $730,000 by 2030, with a bull case of $1.5 million. ARK Invest manages about $16 billion, focusing on disruptive tech and crypto stocks like Circle and Coinbase. While ARK's flagship ETF ARKK has seen volatile returns, Wood remains confident in Bitcoin's long-term potential as digital gold and an institutional asset. Investors should note the high growth targets require exceptional annual gains and consider risks of volatility and concentration in ARK's portfolio.
Cathie Wood and ARK Invest's Bitcoin predictions provide context for cryptocurrency market activity on Pluang as of Nov 07, 2026 22:02 WIB. Of 50 major cryptocurrencies priced on Pluang, 12 rose and 37 fell today. Notable movers include EGLD at Rp57,006 with a 1-day change of -3.83% and a typical hold time of 86 days, LUNC at Rp0,722 down 3.70%, and KSM at Rp59,118 down 3.58%, with EGLD seeing 96% buy orders versus 4% sell orders, the most notable figure.
LayerZero (ZRO) fell 12.77% in 24 hours, leading declines among major cryptocurrencies as 75 of the top 90 coins lost value. Other notable drops include Ethena (ENA) down 11.49%, Worldcoin (WLD) down 10.95%, and Uniswap (UNI) down 10.67%. Meanwhile, ...
Valour launched a new exchange-traded product (ETP) for the PUMP token on Sweden's Spotlight Stock Market, allowing investors to access PUMP through traditional brokerage accounts with a 1.9% management fee. Despite this institutional milestone, PUMP...
Robert Kiyosaki, author of "Rich Dad Poor Dad," has long advocated Bitcoin, gold, and silver as financial assets. Despite his bold price predictions for these assets, none of his nine checked price targets met their deadlines, though five were reache...
Ethereum is trying to stabilize near $2,245 after a sharp decline, but ongoing institutional selling has led to $365 million in ETF outflows over one week. The key support level at $2,200 is under threat, with potential further drops to $2,100 or eve...
Clarivate PLC's shares surged 40% following a strong third-quarter performance and a $600 million divestment in life sciences, which helped reduce the company's leverage and sharpen its business focus. Despite modest organic growth and some leverage ...
